Effect of PACAP on Bacterial Adherence and Cytokine Expression in Intestinal Cell Cultures by Illés, Anita et al.
UN
CO
RR
EC
TE
D P
RO
OF
Journal : Large 10989 Article No : 9748 Pages : 8 MS Code : IJPR-D-18-00106 Dispatch : 17-8-2018
Vol.:(0123456789) 
International Journal of Peptide Research and Therapeutics 
https://doi.org/10.1007/s10989-018-9748-z
Effect of PACAP on Bacterial Adherence and Cytokine Expression 
in Intestinal Cell Cultures
A. Illes1,2 · G. Horvath1  · E. Schafer3 · M. Kerenyi4 · O. Karadi5 · B. Opper1 · G. Toth6 · D. Reglodi1
Accepted: 16 August 2018 
© Springer Nature B.V. 2018
Abstract
Bacterial adhesion is a crucial event of intestinal pathological conditions evoked by bacterial infections. Pituitary adenylate 
cyclase activating polypeptide (PACAP) is an endogenous neuropeptide having a widespread distribution throughout the 
entire body including the digestive tract. It has diverse physiological functions in the gastrointestinal system, including pro-
tective effects in several models of intestinal inflammatory conditions. However, its effects on bacterial adherence and the 
inflammatory reactions as a result of that have not been elucidated yet. The aim of our study was therefore to investigate the 
effect of PACAP on bacterial adherence and cytokine expression upon lipopolysaccharide (LPS) exposure. Small intestinal 
INT407 and colonic Caco-2 cells were treated with PACAP prior to exposure to bacteria (Escherichia coli, Salmonella 
Typhimurium, Klebsiella pneumoniae, Enterococcus faecalis) and colonies were counted. PACAP had no significant influ-
ence on bacterial adhesion, as it did not change the number of colonies of investigated bacteria. However, PACAP was able 
to counteract the LPS-induced increases in the expression of the cytokines IL-8 and CXCL-1 in INT407 cells, as assessed 
by cytokine array. These results indicate that while PACAP has no direct effect on bacterial adherence, it can influence the 
cytokine expression of intestinal cells upon endotoxin-induced exposure, possibly contributing to the known anti-inflam-
matory actions of PACAP in the intestinal system.
Keywords Bacterial adherence · Pituitary adenylate cyclase activating polypeptide · Intestinal cell cultures · 
Lipopolysaccharide · Cytokine expression
Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP) 
is a pleiotropic neuropeptide belonging to the secretin/
glucagon/vasoactive intestinal peptide family. It was first 
identified in ovine hypothalamus based on the efficacy on 
influencing adenylate cyclase activity (Miyata et al. 1989). 
PACAP has a widespread distribution in the body and exerts 
a wide range of physiological effects also in the gastrointes-
tinal system (Somogyvari-Vigh and Reglodi 2004; Horvath 
et al. 2016; Reglodi et al. 2018). The occurrence and func-
tions of PACAP and its receptors can be well demonstrated 
in neuroendocrine and interstitial cells, in the myenteric and 
submucosal plexus in the entire length of the gastrointes-
tinal tract and also in the pancreas, gall bladder and liver 
(Arciszewski et al. 2015; Ji et al. 2013; Koves et al. 1993; 
Oh et al. 2005; Vu et al. 2016; Zhang et al. 2006; Reglodi 
et al. 2018). Among others, PACAP influences motility of 
the intestinal wall (Fujimiya and Inui 2000), inhibits pace-
maker activity of interstitial cells of Cajal (Wu et al. 2015) 
and regulates sphincter function (Farre et al. 2006). PACAP 
affects release of brain-derived neurotrophic factor in intes-
tinal smooth muscle cells and influences gastric juice secre-
tion (Al-Qudah et al. 2015; Reglodi et al. 2018).
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Several in vivo and in vitro studies confirmed the general 
cytoprotective, antiapoptotic, antioxidant, and anti-inflam-
matory effects of PACAP (Reglodi et al. 2012; Ferencz et al. 
2009; Horvath et al. 2010; Vaudry et al. 2009). Our previous 
studies investigating cytoprotective effects have revealed that 
PACAP is able to exert ambivalent effects on cell viability in 
the small intestinal INT407 cells depending on the applied 
stressor and the timing of application (Illes et al. 2017). The 
anti-inflammatory activity of PACAP can be ascribed to inhi-
bition of immune and inflammatory cells. PACAP decreases 
the release of inflammatory chemokines and cytokines such 
as TNF-α and IL-6, inhibits chemotaxis and phagocytosis. 
Hence, it is an important endogenous immunomodulatory 
peptide in many different models of inflammatory diseases 
(Gomariz et al. 2006). In humans, several studies have pre-
viously shown changes in PACAP level in colon diseases. 
An earlier study found significantly lower levels of PACAP 
in sigmoid colon and rectum tumors compared to normal 
healthy tissue (Szanto et al. 2012). Another study described 
significantly higher PACAP levels in patients with symp-
tomatic diverticular disease (Simpson et al. 2009). On the 
contrary, investigations of colon mucosa of children with 
ulcerative colitis found decreases in nerve fibers contain-
ing PACAP (Kaminska et al. 2006, 2007). Furthermore, our 
previous investigations have found marked increase in levels 
of both PACAP isoforms in patients suffering from ulcera-
tive colitis (Horvath et al. 2016). The protective effects of 
endogenous PACAP can also be detected in the colon: in 
dextran sulfate sodium-induced colitis the symptoms of the 
disease in PACAP-deficient mice, such as weight loss, bleed-
ing, diarrhea were markedly more severe than in wild type 
animals (Azuma et al. 2008). Higher morbidity of colorec-
tal tumors in PACAP-deficient mice indicate the possible 
regulatory role of endogenously present PACAP (Nemetz 
et al. 2008). In case of acute ileitis caused by experimental 
Toxoplasma gondii infection in mice, PACAP prophylaxis 
improved survival and anti-inflammatory cytokine response 
(Heimesaat et al. 2014). Besides the beforementioned data, 
our previous studies have shown differences in microbiota 
composition in PACAP deficient mice compared to wildtype 
mice: Bifidobacteria are virtually absent in the knockouts 
(Heimesaat et al. 2017). A recent study has revealed direct 
antimicrobial effect of PACAP38 against Gram-positive and 
Gram-negative bacteria (Starr et al. 2018). All these results 
indicate that PACAP influences directly and indirectly the 
intestinal flora and bacterial colonization, which might be a 
link with increased susceptibility of PACAP deficient mice 
to intestinal inflammatory diseases and tumors.
Adherence of bacteria to the surface of intestinal epi-
thelial cells is a crucial step in intestinal bacterial infec-
tions. Despite the available data on the antimicrobial and 
intestinal effects of PACAP, its role in bacterial adherence 
has not been elucidated yet. Therefore, the aim of our study 
was to explore the role of PACAP in bacterial adhesion in 
small intestinal INT407 and colon adenocarcinoma Caco-2 
cell lines. For this purpose, four different bacteria (Escheri-
chia coli, Enterococcus faecalis, Klebsiella pneumoniae, 
Salmonella Typhimurium) were used. We chose these bac-
teria because Escherichia coli, Enterococcus faecalis and 
Klebsiella pneumonia are commensal bacteria in the gut. 
Although Klebsiella pneumonia is member of the gut flora, 
it can lead to progression of gastrointestinal diseases such 
as Crohn’s disease and ulcerative colitis (Kaur et al. 2018). 
Furthermore, Salmonella Typhimurium was chosen based 
on its pathogenic effect in the small intestine.
In addition, our studies were expanded to obtain further 
information on PACAP’s effects on inflammatory processes 
in the intestinal system using INT 407 cell culture.
Materials and Methods
INT 407 Cell Culture
The INT 407 cell line isolated originally from human embry-
onic intestinal tissue was purchased from ATCC. INT 407 
cells were cultured in Roswell Park Memorial Institute 
(RPMI 1640) medium (Lonza, Switzerland) supplemented 
with 10% fetal bovine serum (Biosera, USA) and 1% peni-
cillin–streptomycin (Biosera, USA). Cells were passaged 
by trypsinization (Trypsin/EDTA; Biosera, USA), followed 
by dilution in RPMI medium containing 10% fetal bovine 
serum. Experiments started 24 h after incubation in humified 
95% air and 5%  CO2 mixture at 37 °C in the medium.
Caco‑2 Cell Culture
The Caco-2 cell line derived from human colon adenocar-
cinoma cell line was from ATCC. Caco-2 cells were cul-
tured in DMEM high glucose/F-12 supplemented with 10% 
fetal bovine serum and 1% penicillin–streptomycin (Bios-
era, USA). Cells were passaged by trypsinization (Trypsin/
EDTA; Biosera, USA), followed by dilution in DMEM 
medium containing 10% fetal bovine serum. Experiments 
started 24 h after incubation in humified 95% air and 5% 
 CO2 mixture at 37 °C in the medium.
Determination of Bacterial Adherence to INT 407 
and CaCo‑2 With and Without PACAP
Before determination of bacterial adhesion, the living INT 407 
and Caco-2 cells were counted by trypan blue and 3 × 105 cells/
well were plated into 24-well tissue culture plates. Both the 
small intestinal INT407 cells and the large intestinal Caco-2 
cells were grown in their media supplemented with 10% fetal 
bovine serum without antibiotics in 5%  CO2 at 37 °C. Half of 
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the 24-well tissue culture plates contained cells, which were 
cultured in the above described medium supplemented with 
400 ng/ml PACAP. Next day the confluent monolayers were 
washed three times with 1 ml Dulbecco’s Phosphate-Buffered 
Saline (DPBS) before infection with 3 × 108 bacterial cells in 
DPBS. After incubation for 3 h at 37 °C in 5%  CO2 each well 
was washed three times with 1 ml of DPBS. To recover adher-
ent bacterial cells, washed INT 407 and Caco-2 cells in each 
well were treated with 1 ml of 0.1% Triton-X100 and 0.25% 
trypsine in PBS for 10 min at room temperature. Each lysate 
was homogenized by repeated pipetting and 10 µl of their ten-
fold serial dilutions were plated on Mueller–Hinton agar plates 
and incubated at 37 °C for 24 h. The following day, the colo-
nies were counted to determine the number of bacteria that 
had adhered to the small and large intestinal cells. Adherent 
bacterial counts were obtained from three independent assays 
with each assay performed in triplicate wells. The investigated 
bacterial cells were Escherichia coli ATCC 25922, Salmonella 
Typhimurium ATCC 14028, Klebsiella pneumoniae ATCC 
13833, Enterococcus faecalis (clinical isolate). Each experi-
ment was repeated six times. Statistical analysis was done 
using one-way analysis of variance p < 0.05 was considered 
as significant.
Cytokine Array
Investigating the effect of PACAP on cytokine expression 
Proteome Profiler Human Cytokine Array kit (R&D Systems, 
Minneapolis, MN, USA) was performed. The investigated 
INT407 cells were plated in six-well plates and the follow-
ing experimental groups were created: (1) control group of 
cells, (2) cells treated with 100 nM PACAP alone for 24 h, (3) 
cells exposed to 100 ng/ml LPS for 24 h and (4) cells treated 
with 100 nM PACAP 2 h prior to 24 h-long 100 ng/ml LPS 
exposion. After incubation, supernatants were collected and 
were carried out according to the manufacturer’s protocol. 
The kit contains all necessary contents. Briefly, after block-
ing the membranes for 1 h and adding the reconstituted Detec-
tion Antibody Cocktail for another 1 h at room temperature, 
membranes were incubated with sample/antibody mixture 
at 2–8 °C overnight. After washing, horseradish peroxidase-
conjugated streptavidin was added for 30 min, then membranes 
were exposed to a chemiluminescent reagent. Array data were 
analyzed using ImageJ software. The experiment was repeated 
three times. Statistical analysis analysis was performed by 
two-way analysis of variance. p < 0.05 was considered as 
significant.
Results
Effect of PACAP on Bacterial Adhesion
To investigate the effect of PACAP on bacterial adhesion 
PACAP-pretreated and non-pretreated INT407 and Caco-2 
cell cultures were infected with the following bacteria: 
Escherichia coli ATCC 25922, Salmonella Typhimurium 
ATCC 14028, Klebsiella pneumoniae ATCC 13833 and 
Enterococcus faecalis (clinical isolate). The assay is based 
on studying the growth of bacteria being able to adhere to 
cells in vitro. In the current experiment, the influence of 
PACAP on the number of bacterial colonies adhered to small 
and large intestinal cells was investigated. PACAP pretreat-
ment of INT407 cells was not able to influence the bacte-
rial adherence (Fig. 1a). Furthermore, similarly to INT407 
cells, infections of colon adenocarcinoma-derived Caco-2 
cells could not be altered by PACAP-pretreatment (Fig. 1b).
Effect of PACAP on Cytokine Expression in INT407 
Cells
To elucidate whether PACAP has an effect on cytokine 
expression in INT407 cells, we used human cytokine array 
(Figs. 2, 3). PACAP alone significantly elevated the expres-
sion of IL-8 and IL-18 changed slightly the expression of 
CXCL-1 (C-X-C motif ligand 1) and MIF (macrophage 
migration inhibitory factor). 100 ng/ml LPS exposure led 
to higher levels of CXCL-1, IL-8, IL-18 and MIF. These 
changes were significant in case of IL-8 and IL-18. PACAP-
pretreatment was able to attenuate the LPS-induced elevated 
expression of IL-8 and CXCL-1. Both PACAP and LPS 
exerted a slight, but not significant, activating effect on MIF.
Discussion
In the present study we found that PACAP could alter the 
cytokine expression of INT407 small intestinal cells alone 
and especially after LPS exposure, indicating that the 
decreased cytokine levels after endotoxin insult can be an 
additional factor in its anti-inflammatory effect in several 
intestinal inflammatory conditions. However, we did not 
find any direct effect on bacterial adhesion, suggesting that 
PACAP does not affect bacterial adhesion on intestinal cells 
directly, but is rather involved in the inflammatory reactions 
induced by different pathogens.
Our finding, that PACAP did not directly influence bac-
terial adhesion under the applied experimental conditions, 
is of importance in light of previous findings indicating 
that PACAP might have direct effects on bacteria and other 
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pathogens. The first direct anti-microbial effects were proven 
in Tetrahymena thermophila, a protozoon, where PACAP 
acted as a chemorepellent (Mace et al. 2000), through the 
same receptor as lyzozyme (Hassenzahl et al. 2001). A sub-
sequent study found antiparasitic activity against another 
parasite, Trypanosoma brucei (T. brucei). Both VIP and 
PACAP killed the infective bloodstream form but not the 
noninfective insect form of the parasite (Gonzalez-Rey et al. 
2006). Parasite integrity was destroyed through a mecha-
nism involving their entry and accumulation into the cyto-
sol (Gonzalez-Rey et al. 2006). A recent study has proven 
that PACAP and its related peptides and analogs are able 
to exert direct antibacterial effects (Starr et al. 2018). Both 
PACAP38 and 27, as well as related peptides, VIP and secre-
tin, had antibacterial effects against Gram-negative bacteria, 
such as Escherichia coli. PACAP could act against the Gram 
positive Staphylococcus aureus. Another assay showed that 
PACAP had moderate sterilizing effect against Pseudomonas 
aeruginosa and Escherichia coli, an effect less pronounced 
by the other peptides. PACAP even had a moderate activity 
against Bacillus cereus (Starr et al. 2018). The mechanism 
of this effect was found to be a membrane permeabiliza-
tion effect, without causing toxic side effects, as shown by 
the undisturbed hemolytic activity on red blood cells (Starr 
Fig. 1  Effect of PACAP pre-
treatment on bacterial adhesion 
in INT407 (a) and Caco-2 (b) 
cells infected with Escherichia 
coli, Salmonella Typhimurium, 
Klebsiella pneumoniae or Ente-
rococcus faecalis 
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et al. 2018). All these data point to the possibility of PACAP 
acting directly on bacteria. We hypothesized that PACAP 
might also influence the adhesion of bacteria to the intestinal 
wall, but we found no effect in the adhesion assay. There-
fore, based on our currect knowledge, it seems that PACAP 
can exert a protective effect on bowel inflammatory condi-
tions via both direct antibacterial as well as cytoprotective 
actions, without influencing the adhesion of bacterial to the 
intestinal wall.
As a next step, therefore, we investigated the effects 
of PACAP on cytokine expression of INT407 cells. As 
PACAP is a known modulator of inflammatory cytokine 
and chemokine production in various cells, we aimed at 
testing this effect in small intestinal cells. We found that 
PACAP altered the expression of several cytokines. IL-8 
is a member of the chemokine family identified as a strong 
chemotactic factor (Baggiolini et al. 1989). Interleukin-8 
plays a crucial role in inflammatory, autoimmune and 
infectious diseases (Harada et al. 1994; Koch et al. 1992; 
Smyth et al. 1991). In our present study, we detected ele-
vated expressions of IL-8 upon exposure to LPS. PACAP 
was able to counteract the induction of IL-8 expression. 
Our finding is in accordance with those of Zhang et al. 
(2005), who found expression-decreasing effect of PACAP 
in ARPE cells stimulated with IL-1β. Besides IL-8, we 
found significantly elevated expression of IL-18 in LPS-
induced samples, but in this case no effect of PACAP on 
it could be observed. Moreover, increase in expression of 
CXCL-1 could be measured upon LPS exposure. PACAP-
pretreatment behaved in an opposite way, it was able to 
significantly decrease the activation of CXCL-1. Delgado 
et  al. have previously decribed expression-decreasing 
effect of PACAP in case of LPS-stimulated peritoneal 
macrophages and microglial cells (2001, 2002). In sum-
mary, PACAP is able to alter the expression of several 
cytokines. This has been demonstrated in many different 
cell and tissue types, such as lymphocytes (Wang et al. 
1999), astrocytes and microglial cells (Gottschall et al. 
1994; Delgado et  al. 2002), in the retina in a chronic 
hypoperfusion model (Szabo et al. 2012) and in the kidney, 
in diabetic and ischemic nephropathy (Horvath et al. 2010; 
Banki et al. 2013). The effects of PACAP on the cytokine 
expression varies between cells and also depends on the 
type of injury. In many cases, PACAP alone does not 
affect cytokine expression, but can counteract the injury-
induced alterations (Szabo et al. 2012). Our observations 
indicate that while PACAP has no direct action on the 
bacterial adhesion to the intestinal wall, it can counteract 
the endotoxin-induced effects on cytokine expression, pos-
sibly contributing to the well-known intestinal protective 
effects of the peptide.
Fig. 2  Representative human cytokine array showing the expression 
of various cytokines in control INT-407 cells (a), cells treated with 
100 nM PACAP (b), cells exposed to 100 ng/ml LPS (c), treatment 
with 100  nM PACAP 2  h prior to 100  ng/ml LPS stimulation (d). 
(1) Changes of CXCL-1 (1), IL-8 (2), IL-18 (3) and MIF (4) could 
be detected. LPS-induced changes of CXCL-1 (1) and IL-8 (2) were 
counteracted by PACAP-pretreatment. Other spots, where no sig-
nificant changes were observed are (from upper left corner, without 
numbers): CCL-1, CCL-2, MIP-1α, RANTES, CD40 ligand, C5a, 
CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, IFN-γ, 
IL-1a, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, 
IL-13, IL-16, IL-17A, IL-17E, IL-18, IL-21, IL-27, IL-32α, MIF, 
Serpin E1, TNF-α, TREM-1
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